Symptom Burden and Blood Counts in Patients With Polycythemia Vera in the United States: An Analysis From the REVEAL Study

Stein, 2015, Polycythemia vera: an appraisal of the biology and management 10 years after the discovery of JAK2 V617F, J Clin Oncol, 33, 3953, 10.1200/JCO.2015.61.6474 Mehta, 2014, Epidemiology of myeloproliferative neoplasms in the United States, Leuk Lymphoma, 55, 595, 10.3109/10428194.2013.813500 Johansson, 2006, Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia, Semin Thromb Hemost, 32, 171, 10.1055/s-2006-939430 Tefferi, 2008, Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy, Am J Hematol, 83, 491, 10.1002/ajh.21183 Emanuel, 2012, Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs, J Clin Oncol, 30, 4098, 10.1200/JCO.2012.42.3863 Marchioli, 2013, Cardiovascular events and intensity of treatment in polycythemia vera, N Engl J Med, 368, 22, 10.1056/NEJMoa1208500 Arber, 2016, The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, Blood, 127, 2391, 10.1182/blood-2016-03-643544 Mesa, 2016, Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark survey, BMC Cancer, 16, 167, 10.1186/s12885-016-2208-2 Finazzi, 2005, Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study, Blood, 105, 2664, 10.1182/blood-2004-09-3426 Baxter, 2005, Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders, Lancet, 365, 1054, 10.1016/S0140-6736(05)71142-9 Tefferi, 2013, Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study, Leukemia, 27, 1874, 10.1038/leu.2013.163 Tefferi, 2017, Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management, Am J Hematol, 92, 94, 10.1002/ajh.24607 Schafer, 2006, Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia, Blood, 107, 4214, 10.1182/blood-2005-08-3526 Spivak, 2010, Narrative review: thrombocytosis, polycythemia vera, and JAK2 mutations: the phenotypic mimicry of chronic myeloproliferation, Ann Intern Med, 152, 300, 10.7326/0003-4819-152-5-201003020-00008 Pourcelot, 2014, Cytokine profiles in polycythemia vera and essential thrombocythemia patients: clinical implications, Exp Hematol, 42, 360, 10.1016/j.exphem.2014.01.006 Ahn, 2007, Isolated monocular visual loss as an initial manifestation of polycythemia vera, J Neurol Sci, 258, 151, 10.1016/j.jns.2007.03.014 Gangat, 2008, Pruritus in polycythemia vera is associated with a lower risk of arterial thrombosis, Am J Hematol, 83, 451, 10.1002/ajh.21156 Parija, 2008, Polycythemia vera presenting with bilateral papilledema: a rare case report, Indian J Ophthalmol, 56, 327, 10.4103/0301-4738.41418 Rai, 2013, An unusual psychiatric presentation of polycythaemia ‘Difficulties lie in our habits of thought rather than in the nature of things’ Andre Tardieu, BMJ Case Rep, 2013, 10.1136/bcr-2012-008215 Yang, 2013, Delayed choroidal and retinal blood flow in polycythaemia vera patients with transient ocular blindness: a preliminary study with fluorescein angiography, Br J Haematol, 161, 745, 10.1111/bjh.12290 Passamonti, 2000, Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients, Haematologica, 85, 1011 Spivak, 2002, Polycythemia vera: myths, mechanisms, and management, Blood, 100, 4272, 10.1182/blood-2001-12-0349 Raedler, 2014, Diagnosis and management of polycythemia vera: proceedings from a multidisciplinary roundtable, Am Health Drug Benefits, 7, S36 Reiter, 2016, How we identify and manage patients with inadequately controlled polycythemia vera, Curr Hematol Malig Rep, 11, 356, 10.1007/s11899-016-0311-8 Harrison, 2017, The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey, Ann Hematol, 96, 1653, 10.1007/s00277-017-3082-y Barosi, 2013, Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project, Blood, 121, 4778, 10.1182/blood-2013-01-478891 Patel, 2016, New strategies in myeloproliferative neoplasms: the evolving genetic and therapeutic landscape, Clin Cancer Res, 22, 1037, 10.1158/1078-0432.CCR-15-0905 Barbui, 2018, Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European Leukemia Net, Leukemia, 32, 1057, 10.1038/s41375-018-0077-1 Barosi, 2009, Response criteria for essential thrombocythemia and polycythemia vera: result of a European Leukemia Net consensus conference, Blood, 113, 4829, 10.1182/blood-2008-09-176818 Scherber, 2011, The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients, Blood, 118, 401, 10.1182/blood-2011-01-328955 Barbui, 2015, White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study, Blood, 126, 560, 10.1182/blood-2015-04-638593 Geyer, 2015, Impact of inflammation on myeloproliferative neoplasm symptom development, Mediators Inflamm, 2015, 284706, 10.1155/2015/284706 Geyer, 2016, Symptomatic profiles of patients with polycythemia vera: implications of inadequately controlled disease, J Clin Oncol, 34, 151, 10.1200/JCO.2015.62.9337